Berita Kesehatan
World Bronchiectasis Day 2022
Senin, 04 Jul 2022 14:43:12

James D. Chalmers, Timothy Aksamit, Stefano Aliberti, Raja Dhar, Lucy C. Morgan

European Respiratory Journal 2022 59: 2201249; DOI: 10.1183/13993003.01249-2022

Extract

On 1 July 2022 we celebrate the first World Bronchiectasis Day. The day is an opportunity to raise awareness of the disease globally, provide information and support to patients, and to promote improved clinical services and more research into this neglected disease.

International organisations come together to raise awareness of bronchiectasis on 1 July 2022: World Bronchiectasis Day https://bit.ly/3tPH7EU

Acknowledgements

World Bronchiectasis Day is supported by the US COPD Foundation, the American Thoracic Society, EMBARC: the European Bronchiectasis Network, the European Lung Foundation, NTM Information and Research, the Lung Foundation of Australia, the American Lung Association, Lovexair Foundation, the Japanese Respiratory Society, the Chinese Thoracic Society, Global Allergy and Airways Patient Platform, the Indian Chest Society, the American College of Chest Physicians, the American Association for Respiratory Care, the South African Thoracic Society, the US COPD Coalition, Running on Air and the Cystic Fibrosis Foundation.

Footnotes

  • L.C. Morgan is the Chair of Lung Foundation Australia. J.D. Chalmers and T. Aksamit are co-chairs of World Bronchiectasis Day 2022 international planning committee. T. Aksamit is the Director of Bronchiectasis and NTM360, COPD Foundation.

  • Conflicts of interest: J.D. Chalmers reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, Insmed, Janssen, Novartis, Pfizer and Zambon; and grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Science, Insmed and Novartis, outside of the submitted work. S. Aliberti reports personal fees from AstraZeneca, Bayer Healthcare, Chiesi, GlaxoSmithKline, Grifols, Insmed, Menarini, Zambon and ZetaCube; and grants from Chiesi. All other authors report no conflicts of interest.

  • Received June 18, 2022.
  • Accepted June 20, 2022.